Survodutide Meets Phase 3 Endpoints in SYNCHRONIZE-2: What the Dual Agonist Readout Means
Boehringer Ingelheim has reported positive Phase 3 results for survodutide (BI 456906), its investigational glucagon/GLP-1 receptor dual agonist, in adults with overweight or obesity and type 2 diabetes. Full results from the SYNCHRONIZE-2 trial were presented October 1, 2026 at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in the New England Journal of Medicine.
SYNCHRONIZE-2 enrolled 755 adults and randomized them to survodutide or placebo over 76 weeks. The trial met both co-primary endpoints - percent change in body weight from baseline and the share of participants losing at least 5 percent of body weight - under both the treatment-regimen and efficacy estimands.
On the efficacy estimand, average weight loss reached up to 13.1 percent with survodutide versus 3.1 percent with placebo, and 79.3 percent of treated participants lost at least 5 percent of body weight versus 32.7 percent on placebo. Glycemic control improved as well: HbA1c fell by up to 1.21 points from a 7.4 percent baseline, and waist circumference dropped by 11.1 centimeters. Gastrointestinal events were the main tolerability issue, with an 18 percent discontinuation rate on survodutide versus 1.2 percent on placebo.
Regulatory context matters. Survodutide is investigational and not approved anywhere. The molecule previously received US Breakthrough Therapy designation and EU PRIME status for MASH, and a body-composition sub-study from the related SYNCHRONIZE-1 trial was also presented at EASD. Zealand Pharma, Boehringer Ingelheim development partner, said it anticipates results from the SYNCHRONIZE-CVOT cardiovascular outcomes trial later in 2026.
For researchers tracking the peptide field, the readout is a data point for the glucagon/GLP-1 dual-agonist class alongside approved GLP-1 and GIP/GLP-1 products. As with every pipeline milestone, the findings belong to the specific candidate and the population studied. They change no label and authorize no use; that remains the FDA decision to make through its standard review process.